H. Lundbeck A/S

New RESOLUTION trial results show Vyepti® (eptinezumab) significantly reduces monthly migraine days (MMDs) in patients with chronic migraine and medication-overuse headache, with rapid benefits observed.

The neurodegenerative disorder therapeutics market is projected to grow from $18.53 billion in 2023 to $28.33 billion in 2028 at a CAGR of 9.0%, driven by factors like aging population, rising prevalence of neurodegenerative disorders, and strategic collaborations among pharmaceutical companies.

Longboard Pharmaceuticals reports Q3 2024 financials, including a positive EMA opinion for bexicaserin in children aged 2 and above, and the initiation of a Phase 3 trial for Dravet syndrome. The company also announces an agreement for Lundbeck to acquire Longboard. Financial highlights show cash, cash equivalents, and short-term investments totaling $288.4 million, with research and development expenses increasing to $21.5 million.

H. Lundbeck A/S announced Vyepti® (eptinezumab) met primary and secondary endpoints in SUNRISE trial, reducing monthly migraine days significantly compared to placebo. Lundbeck plans to discuss with regulatory authorities to make Vyepti available in Asia. Safety profile was similar to placebo, with COVID-19 and nasopharyngitis as most common adverse events.

Lundbeck's Vyepti® (eptinezumab) met primary and secondary endpoints in phase III SUNRISE trial, showing significant reductions in monthly migraine days and early preventive effects, with plans to discuss regulatory approval for Asian markets.

DelveInsight's 'Epilepsy Pipeline Insight, 2024' report details 75+ companies developing 90+ therapies, including RLS103, CT-010, EQU 001, and others, with insights on mechanism of action, route of administration, and clinical trials. Key companies include Novartis, Pfizer, Sanofi, and Takeda, among others.

The Anxiety Disorders and Depression Treatment Market was valued at USD 12.2 billion in 2023 and is projected to reach USD 16.65 billion by 2032, growing at a CAGR of 3.53%. This growth is driven by the rising prevalence of anxiety disorders and depression, advancements in pharmaceutical therapies, and increased awareness and destigmatization of mental health issues.

Charles River Laboratories launched its Retrogenix Non-Human Protein Library to aid biopharmaceutical clients in assessing off-target binding, de-risking in vivo studies, and selecting non-human species, enhancing drug discovery precision and efficiency.

Tau Inhibitors Clinical Trial Pipeline Analysis shows 25+ key companies expected to transform treatment, with increased funding accelerating advancements in neurodegenerative disease therapies.